Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Can you drink too much water? Experts say yes

Drinking adequate amounts of water is said to prevent kidney damage, help lose weight and increase concentration. However experts now warn that drinking eight glasses of water a day is not good after all – and could be harmful. They say that scientific claims behind long-standing government guidelines are worse than ‘nonsense’. The NHS – along with leading doctors and nutritionists – advises the public to drink about 1.2 litres (or two-and-a-half pints) of water per day.

13 Jul 2011

Cardiology study looks at sodium and potassium in diet

A new study suggests that in addition to cutting the amount of sodium in their diets to improve heart health, Americans should also increase consumption of a key mineral found in many fruits and vegetables, potassium.

11 Jul 2011

Arizona E. coli related death triggers warning

The Center for Disease Control and Prevention (CDC) and the Arizona Department of Health announced last Friday that a man who recently traveled to Germany was infected by the German E. coli outbreak. The man died from kidney complications. This death was the first U.S. fatality of the relentless epidemic. According to the World Health Organization, 52 have been killed in the outbreak.

10 Jul 2011

ASN President discusses latest information about diabetic nephropathy at ADA

ASN President Dr. Joseph V. Bonventre, MD, PhD, spoke at the American Diabetes Association's annual meeting, 71st Scientific Session, this June in San Diego. Dr. Bonventre was featured at a symposium entitled "New Concepts in Diagnosing and Treating Diabetic Nephropathy."

6 Jul 2011

Periodontal disease can affect woman's chance of conceiving

Professor Roger Hart told the annual meeting of the European Society of Human Reproduction and Embryology that the negative effect of gum disease on conception was of the same order of magnitude as the effect of obesity.

5 Jul 2011

Anti-inflammatory drugs may increase risk of atrial fibrillation

Commonly used painkillers to treat inflammation are linked to an increased risk of irregular heart rhythm, concludes a study published on bmj.com today.

5 Jul 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

FDA directive on anemia drug in kidney disease patients

The U.S. Food and Drug Administration (FDA) has issued new warnings for anemia drugs for patients with kidney disease after studies suggested such drugs could increase stroke risks. The new warnings are the latest to hit the widely used medications since 2007, when the FDA first said they could cause fatal side effects.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

The University of Virginia Health System has received a $300,000 grant to study the "Call to Health" model, which uses text messages, stress reduction and other techniques to help African-American women manage type 2 diabetes.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Nephropathy News and Research

Further Reading

Can you drink too much water? Experts say yes

Cardiology study looks at sodium and potassium in diet

Arizona E. coli related death triggers warning

ASN President discusses latest information about diabetic nephropathy at ADA

Periodontal disease can affect woman's chance of conceiving

Anti-inflammatory drugs may increase risk of atrial fibrillation

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

FDA directive on anemia drug in kidney disease patients

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Study finds high prevalence of diabetic kidney disease in the U.S.

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Study: Dyslexia gene controls cilia in brain neurons

Targeting activity of PKD1 may be beneficial for treatment of polycystic kidney, liver disease

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News